Integra resets by fixing supply and riding reimbursement tailwinds

Integra LifeSciences used its update at the ongoing 2026 J.P. Morgan Healthcare Conference in San Francisco to frame 2025 and 2026 as a deliberate transition period. The company described a shift from disruption and remediation toward more predictable execution, supported by product relaunches, a more resilient supply chain, and reimbursement changes that could make parts of its wound portfolio more economically attractive in outpatient settings.

Integra spent a meaningful portion of the presentation on its “two horizon” plan. As presented, Horizon 1 is about rebuilding a sustainable foundation through quality systems, supply chain reliability, and better working capital discipline. Management emphasised that 2025 demand exceeded what it could supply, and that improved planning and manufacturing consistency are expected to translate into better service levels and greater ability to meet demand, alongside stronger cash flow and better profitability over time.

Horizon 2 is meant to deliver faster growth through clinical evidence generation, new indications for existing tissue technologies, and investment in neurosurgery and ear, nose and throat (ENT), enabled by a 2025 portfolio prioritisation exercise that management said helps direct capital toward higher growth and higher margin areas. The company positioned these workstreams as advancing simultaneously, with foundational improvements intended to make growth initiatives more repeatable and scalable.

The practical test of this reset is whether Integra can restore availability in product lines that have faced recalls or prolonged market exits. Multiple products have been affected by quality issues and remediation, which has constrained supply. Integra noted it relaunched PriMatrix and Durepair in Q4 2025, and highlighted SurgiMend as a planned Q4 2026 launch. GlobalData’s SKU analysis suggests early traction from this relaunch, with PriMatrix sales in US healthcare institutions rising by more than 80% between 2024 and 2025.

To further support these efforts, the company discussed supply resilience initiatives including a new Braintree, Massachusetts manufacturing facility expected to be operational in the first half of 2026. Looking across the recalls and relaunch priorities disclosed to date, tissue-based wound and reconstruction products appear to be at the centre of both the recent disruption and the planned recovery, making execution in this franchise central to regaining momentum.

Tissue technologies are a meaningful part of Integra’s revenue mix and investor narrative, and the tissue-engineered skin substitute (TESS) segment is one of the faster-growing areas within it. GlobalData estimates the TESS market to grow from $2.6b in 2025 to $3.9b by 2030, implying a compound annual growth rate of 8.6%.

Within this market, GlobalData estimates that Allergan, part of AbbVie, leads with a 24% share, followed by Integra at 16% and Organogenesis at 14%. This presents a substantial market opportunity, but Integra will likely only capture it if it can sustain stable manufacturing and build credible clinical evidence as utilisation grows with aging populations and broader chronic wound and reconstruction demand.

In its presentation, Integra also pointed to Centers for Medicare and Medicare Services (CMS) reimbursement changes for skin substitutes that took effect on January 1, 2026. These changes shift most products to a standardised payment of about $127.3 per square centimetre across sites of care. Integra argued that its pricing sits within the new rate, making products not only clinically compelling but also easier to justify economically, without implying margin compression.

In ENT, the company noted that Acclarent’s first year post-acquisition tracked to expectations, while balloon sinuplasty faced unanticipated 2025 declines tied to reimbursement dynamics. GlobalData’s estimates underscore Integra’s scale in that category, with Acclarent accounting for an estimated $518m in 2025 revenue, over 70% share of the $810m balloon sinuplasty market. If reimbursement headwinds ease, that concentration could quickly swing segment performance.

Integra’s story in early 2026 is less about a single breakthrough and more about earning the right to grow again. Management said it is aiming for modest growth in 2026 and is working toward organic growth at least in line with its served markets. For that to be realistic, the key levers are likely straightforward: consistent product supply, clean execution on relaunches, and sustained clinical and economic relevance in fast-growing wound categories.

Sign up here to receive daily updates on the latest healthcare industry trends emerging from the J.P. Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.

“JPM26: Integra resets by fixing supply and riding reimbursement tailwinds” was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.